KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) EBT Margin (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed EBT Margin for 15 consecutive years, with 0.9% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 1605.0% to 0.9% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 6.82% through Dec 2025, down 2161.0% year-over-year, with the annual reading at 6.82% for FY2025, 2161.0% down from the prior year.
  • EBT Margin for Q4 2025 was 0.9% at Supernus Pharmaceuticals, up from 30.17% in the prior quarter.
  • The five-year high for EBT Margin was 25.58% in Q3 2024, with the low at 30.17% in Q3 2025.
  • Average EBT Margin over 5 years is 6.01%, with a median of 6.54% recorded in 2023.
  • The sharpest move saw EBT Margin surged 2826bps in 2024, then crashed -5575bps in 2025.
  • Over 5 years, EBT Margin stood at 1.29% in 2021, then surged by 1529bps to 21.0% in 2022, then plummeted by -97bps to 0.6% in 2023, then skyrocketed by 2414bps to 15.15% in 2024, then crashed by -106bps to 0.9% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 0.9%, 30.17%, and 10.07% for Q4 2025, Q3 2025, and Q2 2025 respectively.